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Abstract
Background: Hemolytic-uremic syndrome (HUS) is a clinical triad of microangiopathic hemolytic anemia,
impaired renal function and thrombocytopenia, primarily affecting pre-school-aged children. HUS can be
classified into diarrhea-associated HUS (D+HUS), usually caused by Shiga toxin-producing Escherichia coli (STEC), and
non-diarrhea-associated HUS (D−HUS), both with potentially serious acute and long-term complications. Few data
exists on the clinical features and long-term outcome of HUS in Norway. The aim of this paper was to describe these
aspects of HUS in children over a 10-year period.
Methods: We retrospectively collected data on clinical features, therapeutic interventions and long-term aspects
directly from medical records of all identified HUS cases <16 years of age admitted to Norwegian pediatric
departments from 1999 to 2008. Cases of D+HUS and D−HUS are described separately, but no comparative
analyses were possible due to small numbers. Descriptive statistics are presented in proportions and median
values with ranges, and/or summarized in text.
Results: Forty seven HUS cases were identified; 38 D+HUS and nine D−HUS. Renal complications were common;
in the D+HUS and D−HUS group, 29/38 and 5/9 developed oligoanuria, 22/38 and 3/9 needed dialysis, with
hemodialysis used most often in both groups, and plasma infusion(s) were utilized in 6/38 and 4/9 patients,
respectively. Of extra-renal complications, neurological complications occurred in 9/38 and 2/9, serious
gastrointestinal complications in 6/38 and 1/9, respiratory complications in 10/38 and 2/9, and sepsis in 11/38
and 3/9 cases, respectively. Cardiac complications were seen in two D+HUS cases. In patients where data on
follow up ≥1 year after admittance were available, 8/21 and 4/7 had persistent proteinuria and 5/19 and 4/5 had
persistent hypertension in the D+HUS and D−HUS group, respectively. Two D+HUS and one D−HUS patient were
diagnosed with chronic kidney disease and one D+HUS patient required a renal transplantation. Two D+HUS
patients died in the acute phase (death rate; 5 %).
(Continued on next page)
* Correspondence: gautereier@gmail.com
1Department of Infectious Disease Epidemiology, Norwegian Institute of
Public Health (Nasjonalt Folkehelseinstitutt), Postboks 4404 Nydalen, NO 0403
Oslo, Norway
2Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo,
Norway
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jenssen et al. BMC Infectious Diseases  (2016) 16:285 
DOI 10.1186/s12879-016-1627-7
(Continued from previous page)
Conclusions: The HUS cases had a high rate of complications and sequelae, including renal, CNS-related, cardiac,
respiratory, serious gastrointestinal complications and sepsis, consistent with other studies. This underlines the
importance of attention to extra-renal manifestations in the acute phase and in renal long-term follow-up of HUS
patients.
Keywords: Enterohaemorrhagic E. coli - EHEC, Epidemiology, Haemolytic uraemic syndrome, Shiga toxin
producing E. coli – STEC, clinical outcome, aHUS, SP-HUS
Background
Hemolytic-uremic syndrome (HUS) is a clinical condition
characterized by the triad of impaired renal function, non-
immune hemolytic anemia and thrombocytopenia, and is
considered one of the most common causes of acute
kidney injury (AKI) in children in Europe and the
Western world [1–3]. HUS mainly affects children of
pre-school age [4]. In Norway, HUS is the second most
common cause of AKI in children, and has an esti-
mated average annual incidence rate of 0.5 cases per
100,000 children [5, 6]. This is lower than in most
European countries [7–9].
A common classification of HUS is by clinical presen-
tation; associated with prodromal diarrhea (D+HUS) or
not (D−HUS). Around 90 % of HUS cases in children
are D+HUS [7, 10]. In the Western world, most cases
of D+HUS are caused by infection with Shiga toxin produ-
cing Escherichia coli (STEC-HUS) [4]. According to this
classification, D−HUS mainly consists of HUS caused by
Streptococcus pneumoniae infection (SP-HUS) and HUS
associated with familiar or sporadic genetic disorders of
complement regulation (atypical HUS; aHUS) [11]. This
classification has some limitations. STEC-HUS is generally
considered D+HUS, although some cases may present
without diarrhea [4]. Some of the aHUS cases may present
with diarrhea, but are eventually classified as D−HUS.
Therefore, other classifications define HUS based on both
clinical associations and causal factors [12, 13]. It has been
suggested that some STEC-HUS cases, especially those
with more severe outcome, are genetically predisposed
aHUS cases triggered by an STEC infection [14].
D+HUS patients usually present with signs of entero-
pathic infection; diarrhea, often bloody and/or watery,
abdominal tenderness and more rarely low grade fever
[15]. Renal affection with decreasing diuresis and subse-
quent oliguria and/or anuria usually follows in the esti-
mated 10–15 % who develops HUS, although temporary
renal impairment can be seen due to dehydration in
STEC infections without HUS. Symptoms and complica-
tions from extrarenal involvement may occur in the
acute phase; most often from the central nervous system
(CNS), but also of respiratory, cardiac and gastrointes-
tinal nature [16–18]. D−HUS may present with various
and prolonged atypical symptoms [11].
The clinical features of HUS are a consequence of
microvascular lesions termed thrombotic microangiopa-
thy (TMA). TMA mainly affects arterioles and capillaries
of the kidneys and the CNS and results in impaired
blood vessel flow with subsequent ischemic damage in
the affected organs [4, 19].
Long-term sequelae of HUS are predominantly renal
with reduced glomerular filtration rate, hypertension
and/or prolonged proteinuria [4]. In a large meta-
analysis, it was estimated that renal sequelae without
end stage renal disease (ESRD) occurred in around 25 %
and an outcome of ESRD in 3 % of D+HUS cases [20].
The death rate is considered 3–5 %, but varies between
studies [20, 21]. D+HUS and D−HUS are associated with
similar short and long-term complications, but clinical
signs of kidney dysfunction are considered more fre-
quent in the latter. The death rate is higher in SP-HUS
than D+HUS, especially in the acute phase, although the
long-term renal prognosis for this group is generally
favorable [11, 22].
Treatment of HUS has until recently been supportive:
fluid therapy, dialysis, plasmapheresis/plasma infusion and
treatment of complications [4, 23, 24]. The emergence of
eculizumab, a monoclonal C5 antibody, has now provided
a proven effective treatment of genetic aHUS [25]. Eculi-
zumab has also shown potential in the treatment of
D+HUS, and further studies are currently ongoing [26].
Knowledge on HUS in Norway has been limited. The
first national outbreak of STEC-HUS in Norway, in
which one child died, occurred in 2006 [27]. This out-
break led to the notification criteria of HUS being chan-
ged from STEC-HUS to all D+HUS and brought HUS to
public attention [28]. We recently published national
data focusing on the epidemiological and surveillance
aspects of HUS in children in Norway [5]. There, we
concluded that the incidence of HUS was low compared
to most European countries, but higher than previously
assumed. STEC-HUS is the second most common cause
of acute kidney injury in children in Norway [6], but
national data on sequelae and outcomes has not been
presented before. The primary aim of the current study
is to describe the clinical features, therapeutic interven-
tions and long-term aspects of the cases of D+HUS and
D−HUS included in the epidemiological study.
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Methods
Design
We performed a retrospective, descriptive study of
data collected directly from relevant patient medical
records.
Data collection
Potentially relevant cases were identified through med-
ical record searches for pediatric patients < 16 years of
age initially admitted to a Norwegian hospital from the
1st of January, 1999, to the 31st of December, 2008, with
ICD-10 codes D59.3 (HUS), N17 (AKI) and/or N00/
N01/N05 (acute nephritic syndrome/rapidly progressive
nephritic syndrome/unspecified nephritic syndrome).
The non-HUS ICD-10 codes were included in the search
and evaluated on site to identify potentially misdiag-
nosed cases of HUS. Cases matching the case definitions
seen below were included. Cases that had been partially
treated in Norwegian pediatric departments, but had
initially been admitted for HUS outside of Norway, were
excluded.
All Norwegian hospitals with pediatric capacity were
contacted prior to the data collection to identify relevant
cases. Data were collected from relevant patient medical
records from 24 pediatric departments of Norwegian
hospitals; directly from 18 hospitals. Data from the
remaining six hospitals were collected indirectly as they
confirmed in advance having transferred all relevant
patients to one of the former 18 hospitals. Medical
record data missing from the six hospitals were obtained
by mail. Data were collected on site by two project co-
workers (medical students/authors Jenssen and Hovland),
with two pediatric nephrologists (authors Bangstad
and Bjerre) available for phone consultations in un-
clear and/or difficult cases. The coordinating center
of the study was the Norwegian Institute of Public
Health.
Forms made with EpiData (www.epidata.dk) were used
to register data. The forms were designed through a
pilot project, in which we examined the availability of
relevant variables in standard medical records. The
registered data were stored and encrypted according to
the information security standards of the Norwegian
Institute of Public Health.
Case definitions
A hemolytic-uremic syndrome (HUS) case was defined as:
– a case clinically compatible with all the following
laboratory findings of
○ thrombocytopenia (<150 × 10^9/L), AND
○ anemia (Hgb < 10.5 g/dL) of hemolytic origin,
with elevated serum lactate dehydrogenase (LD)
(>500 U/L), AND
○ acutely reduced renal function (serum creatinine
>35 μmol/L for patients < 1 years of age, > 80 μmol/
L for patients 1–15 years of age), AND EITHER
▪ Reported presence of fragmented red blood
cells (schiztocytes) on peripheral blood smear; a
sign of microangiopathic changes consistent
with hemolysis and an important part of HUS
pathophysiology [1], or
▪ if peripheral blood smear was missing in the
journal; probable clinical HUS confirmed by
consulting a clinician with expertise in pediatric
nephrology
A diarrhea-associated HUS (D+HUS) case was defined
as a HUS case with either:
– a clinical presentation of prodromal diarrhea,
without verifiable causative etiology (probable
STEC-HUS), OR
– STEC-HUS, defined as a HUS case with laboratory-
verified STEC-infection
A D−HUS case was defined as any non-diarrhea-
associated HUS or HUS of verified non-STEC causality.
Variables collected
The following clinical variables were collected: time
from first symptom to admittance; age at admittance;
duration of initial hospitalization; duration of total
time hospitalized; presence of prodromal diarrhea;
presence of prodromal bloody diarrhea; presence of
hypertension at admittance; development of oligoa-
nuria, hypertension and/or proteinuria in the acute
phase; extra-renal complications; death in the acute
phase; laboratory values at admission and minimal/
maximal value (hemoglobin, creatinine, LD, platelet
count, CRP, white blood cell count, sodium).
The following therapeutic intervention variables were
collected: use of dialysis, type of dialysis used, duration
of dialysis; use of plasmapheresis, red blood cell transfu-
sions, platelet transfusions, plasma infusions/exchange,
antibiotics (any indication); renal transplantation per-
formed; use of other therapeutic modalities.
The following long-term/outcome variables were col-
lected: presence of hypertension and/or proteinuria at first
follow-up and at follow up 1 year or more following initial
admission; presence of renal sequelae/long-term com-
plications; estimated glomerular filtration rate and/or
creatinine value at first follow-up and at follow up 1 year
or more following initial admission; death at follow up.
Statistical analysis
Descriptive statistics were calculated using Microsoft
Excel and are presented as proportions and median
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values with ranges. Variables are presented in tables
and/or in text. Estimated glomerular filtration rate
(eGFR) was estimated retrospectively using the height-
independent Pottel eGFR equation [29]. Descriptive
analyses for the D+HUS and D−HUS group were done
separately, but no comparative analyses were done




Forty-seven HUS patients, (16 boys and 31 girls; median
age 2 years, range 5 months to 15 years) were identified
from 1999 up to and including 2008. 38 (81 %) were
D+HUS cases, 23 (61 %) of which had confirmed STEC in-
fection. Nine (19 %) were D−HUS cases; two SP-HUS,
three of verified genetic origin, one specified as Campylo-
bacter-related, and three non-diarrhea-associated cases
with unknown etiology. The genetic HUS cases all
had CD46-mutations; one had an additional C3-
mutation, another had antibodies to Factor H [5].
All but one of the D+HUS cases presented with
diarrhea and 27 (71 %) of these had bloody stools.
The D+HUS case presenting without diarrhea had con-
firmed STEC infection. Two (22 %) of the nine patients
with D−HUS presented with diarrhea, both had bloody
stools. One initially presented with non-bloody diar-
rhea, clinical HUS and mild infection parameters.
Bloody diarrhea was only noted after transfer to a larger
hospital. There the patient developed bacteremia from
a central venous catheter-related Staphylococcus aureus
infection and had Enterococcus faecalis identified in a
urine sample. This patient later had HUS relapses and was
shown to carry both a CD46 and a C3-mutation. The
other D−HUS patient was the above mentioned were only
Campylobacter jejuni was isolated in stool samples and
specified as cause in the medical record. Both were
defined as D−HUS cases due to the etiological cause.
For the D+HUS and D−HUS group, respectively, me-
dian time from first registered symptom to admittance
was 6 and 5 days, initial hospitalization lasted a median
15 and 16 days, whereas 29/38 (76 %) and 5/9 (56 %)
cases developed oligoanuria at some point during initial
admission (Table 1). Two of the D+HUS patients died,
both in the acute phase, with a death rate of 5 %.
None of the D−HUS cases had died at the point of
data assessment.
Few patients had registered blood pressure at admit-
tance. In the D+HUS and D−HUS group, respectively,
4/17 (24 %) and 2/6 (33 %) cases were hypertensive.
However, 30/36 (83 %) D+HUS cases and all eight D−HUS
cases where information on blood pressure was avail-
able had registered hypertension at some point during
initial admission (Table 1).
Non-renal clinical features of D+HUS patients (Table 1)
Different neurological complications were seen in nine
(24 %) of 38 cases in the D+HUS group, and manifested
as follows; two patients with mild brain infarctions;
one with brain microinfarctions; two patients devel-
oped brain edema; one developed brain tamponade;
one had clinical meningitis; one developed intracranial
hematoma following a procedure; one suffered anoxic
brain damage, with brain atrophy and epilepsy. Four of
the patients had seizures in the acute phase, including
two without further neurological complications. In one
patient, brain scanning showed lowered white matter
echogenicity. Finally, one patient showed signs of CNS
affection, manifested as an inability to remember cer-
tain words.
Cardiac complications were seen in two (5 %) patients;
one had multiple myocardial infarctions and cardiac ar-
rest with successful resuscitation, the other developed
pericardial fluid effusion following an episode of sepsis.
Respiratory complications were described in ten
(26 %) cases, with the need of ventilation therapy de-
scribed in nine patients. One patient had pneumothorax.
Three had hydrothorax, one of which did not receive
ventilation therapy. One developed pulmonary collapse
and chronic respiratory failure. The remaining patients
needed ventilation therapy in the process related to
other complications listed here, including sepsis and
neurological events.
Five (13 %) patients had serious gastrointestinal com-
plications. Two patients developed colonic necrosis with
perforation, peritonitis and sepsis, requiring left hemico-
lectomy and subtotal colectomy, respectively. Two pa-
tients experienced gall stone problems, one of them
requiring cholecystostomy. Other gastrointestinal com-
plications included one patient with rectal prolapse and
two with intestinal invagination. One patient in the D
+HUS group also had pancreatic complications, with the
developement of diabetes mellitus.
There were eleven (29 %) cases complicated by sepsis.
Staphylococcus aureus was specified as causative agent
in two, Staphylococcus epidermidis in another two. One
was caused by streptococcal throat infection, one by
Acinetobacter baumannii and one had urosepsis but the
agent was not specified. In the remaining cases, we were
unable to identify the causative agent; two cases were
complications of a perforated intestine and STEC infec-
tion proven in four without conclusive evidence of caus-
ing sepsis. Two patients developed septic shock; in both,
STEC (serotype O87 and O103, respectively) was the
only agent identified.
Non-renal clinical features of D−HUS patients (Table 1)
The most severe symptoms were in the two SP-HUS
patients with septicemia, neurological and respiratory
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complications. Complications included pneumococcal-
induced septic meningitis with acute respiratory failure,
development of brain atrophy, hemiplegia with spastic
convulsions and epileptic activity, neuronal hearing loss
and retinopathy, seizures related to pneumococcal
septic pneumonia with pleural empyema and acute
respiratory failure. Both patients needed ventilator
therapy.
The third case of sepsis in the D−HUS group was of
Staphylococcus aureus origin, after complications with a
central venous catheter.
One D−HUS patient developed gall-stone problems
during admission, eventually needing endoscopic retro-
grade cholangiopancreatography-guided extraction.
Long term sequelae (Table 1)
Follow up data 1 year or more after initial admission
were available in more than half the cases. With the
exception of one case from 2008, all D+HUS medical
records were assessed at least 1 year after being
diagnosed with HUS. The D−HUS medical records
were assessed a minimum of 2 years following pri-
mary admission.
At the first follow up after being released from
hospital, presence of persistent proteinuria was seen in
16/32 (50 %) cases in the D+HUS group and 7/9 (78 %)
cases in the D−HUS group. At follow up at 1 year or
more following initial admission, presence of persistent
proteinuria was seen in 8/21 (38 %) cases and 4/7
(57 %) cases, respectively. Persistent hypertension was
seen in 10/32 (31 %) cases in the D+HUS group and
5/9 (56 %) cases in the D−HUS group at the first
follow up, and in 5/19 (26 %) and 4/5 (80 %) cases at
follow up 1 year or more following initial admission,
respectively.
Within the time frame from initial admission to last
follow up and/or registered follow up assessed in the
data collection, two (5 %) of the 36 D+HUS patients
that survived the acute phase and one (11 %) of the
D−HUS patients had been diagnosed with chronic
Table 1 Clinical features of HUS in children in Norway, 1999-2008
Clinical feature Diarrhoea-associated HUS (N = 38) Non-diarrhea-associated HUS (N = 9)
Time first symptom to admittance (median, days) 6 (4–9) 5 (2–10)
Age at admittance (median, months/years)a 31 (range; 5 months–15 years)a 18 (range; 7 months–6 years)a
Duration of initial hospitalization (median, days) 15 (11–24) 16 (8–42)
Duration of total time hospitalizedb (median, days) 18 (12–24) 16 (8–53)
Prodromal diarrhea (n, %) 37 (97 %) 2 (22 %)
Prodromal bloody diarrhea (n, %) 27 (71 %) 2 (22 %)
Hypertension at admittance (n, %) 4 (24 %) (N = 17) 2 (33 %) (N = 6)
Hypertension registered during admittance (n, %) 30 (83 %) (N = 36) 8 (100 %) (N = 8)
Oligoanuria (n, %) 29 (76 %) 5 (56 %)
Death acute phase (n, %) 2 (5 %) 0 (0 %)
Non-renal complications
Neurological complications (n, %) 9 (24 %) 2 (22 %)
Cardiac complications (n, %) 2 (5 %) 0 (0 %)
Respiratory complications (n, %) 10 (26 %) 2 (22 %)
Gastrointestinal complications (n, %) 5 (13 %) 1 (11 %)
Sepsis (n, %) 11 (29 %) 3 (33 %)
Renal outcome
Proteinuria at first follow-up (n, %) 16 (50 %) (N = 32) 7 (78 %)
Proteinuria ≥ 1 year after initial admission (n, %) 8 (38 %) (N = 21) 4 (57 %) (N = 7)
Hypertension at first follow-up (n, %) 10 (31 %) (N = 32) 5 (56 %)
Hypertension ≥ 1 year after initial admission (n, %) 5 (26 %) (N = 19) 4 (80 %) (N = 5)
Chronic kidney disease (n, %) 2 (5 %) 1 (11 %)
End-stage renal disease (ESRD) 1 (3 %) 0 (0 %)
Results are presented as number of cases, n (%) and median (interquartile range). If data on the feature was not available in all medical records, the number of
cases where available is presented (N = number of cases where available). HUS hemolytic uremic syndrome
aRange; smallest and highest value for illustrational purposes
bTime hospitalized including all readmissions for complications and extensive (not regular) follow-up
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kidney disease, and one had developed ESRD requir-
ing renal transplantation.
Therapeutic interventions (Table 2)
Table 2 presents the therapeutic interventions im-
plemented for all HUS patients. In the D+HUS and
D−HUS group, dialysis was performed in 22 (58 %)
and three (33 %) cases, for a median duration of 8
and 12 days, and the most common modality was
hemodialysis, utilized in 16/22 (73 %) and 2/3 (66 %)
cases needing dialysis, respectively. Duration of dialy-
sis was performed at primary admission only, with
one exception; one patient never recovered kidney
function and continued dialysis for an additional
133 days. Plasmapheresis was performed in three
(8 %) and one (11 %), plasma infusions used in six
(16 %) and four (44 %) and red blood cell transfusions
used in 34 (89 %) and all of the cases in the D+HUS
and D−HUS group, respectively. Antibiotics were
given in 23 (61 %) of D+HUS cases and four (44 %)
of D−HUS cases. However, time of administration was
often unclear or not specified in the medical records.
This also applied to indication for treatment, which
included various conditions such as sepsis, catheter
infection, pneumonia and urinary tract infection.
Laboratory data (Table 3)
Table 3 presents the laboratory values registered
for the two groups. Notably, in the 31 patients in
the D+HUS where available, median hemoglobin
value at admission was 11.1 g/dL.
Discussion
In this nationwide retrospective survey on clinical, thera-
peutic and long-term aspects of hemolytic-uremic
syndrome (HUS) in children in Norway, we describe the
multiorgan burden of this life threatening disease. A
substantial amount of the patients had a complicated
inhospital period and long term renal complications
were common. Over a 10 year period, a total of 47 HUS
cases were identified in the period [5]. D+HUS was most
common with 38 (80 %) cases, of which 23 (61 %) had
confirmed STEC infection. There were nine (19 %) D
−HUS cases; two were caused by pneumococci, three
were of genetic origin, one was specified as caused by
campylobacter and the remaining three had unknown
etiology. Because of the low number of cases and the
diverse etiologies comprising the D−HUS group, direct
comparison between these groups was difficult. Similar
studies exist on the HUS in other countries; with this
work we have presented data on the HUS situation in
Norwegian children, on which knowledge has been
limited.
All but one of the confirmed STEC cases presented
with diarrhea. Two of the D−HUS cases initially
presented with bloody diarrhea; these had documented
atypical causes, and were classified as D−HUS. This re-
flects the fact that some atypical HUS cases may present
with diarrhea and emphasizes the importance of
thorough diagnostic work to avoid potentially misdiag-
nosed cases based on early clinical presentation [4, 13].
This underlines one of the advantages of a more specific
classification of HUS. Concomitantly, the relatively
low frequency of these occurrences in our study also
indicates that the D+/D− classification may be useful,
especially in early etiological considerations. Another
point related to initial presentation is that the median
value of hemoglobin at admission was 11.1 g/dL in the
31 D+HUS cases where available. A high level of
hemoglobin at admission and even at diagnosis has also
been described elsewhere [24]. This may reflect serious
dehydration or that some patients were admitted before
the most acute phase of hemolysis. In either case, this
may be misleading in the early diagnostic work; an
important point to consider when approaching a case





HUS (N = 38)
Non-diarrhea-associated
HUS (N = 9)
Dialysis – any type
(n, %)
22 (58 %) 3 (33 %)
Type of dialysis (n)
− Peritoneal (n, %)
− Hemodialysis (n, %)











8 (5–15) (N = 22a) 12 (7–13) (N = 3)
Plasmapheresis (n, %) 3 (8 %) 1 (11 %)
Red blood cell
transfusion(s) (n, %)
34 (89 %) 9 (100 %)
Platelet transfusion(s)
(n, %)
15 (39 %) 3 (33 %)
Plasma infusion(s) (n, %) 6 (16 %) 4 (44 %)
Antibiotics – any
indication (n, %)
23 (61 %) 4 (44 %)
Ventilation therapy
(n, %)
9 (24 %) 2 (22 %)
ERCP (n, %) 0 (0 %) 1 (11 %)
Cholecystostomy (n, %) 1 (3 %) 0 (0 %)
Renal transplantation
(n, %)
1 (3 %)b 0 (0 %)
Results are presented as number of cases, n (%) and median (interquartile
range). The values for type and duration of dialysis are estimated from those
who received dialysis only, as specified (N = number of cases). HUS hemolytic
uremic syndrome, ERCP endoscopic retrograde cholangiopancreatography
aIncluding the only patient that received dialysis after initial admission
(for an additional 133 days until renal transplantation)
b12 months after initial admission
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with the initial clinical presentation of STEC infection
and D+HUS.
Our data on the D+HUS group were in accordance
with other studies concerning urine production at the
time of admission; 76 % were oligoanuric when admitted
to hospital, and 58 % required dialysis [9, 30]. Neuro-
logical complications, including seizures, brain infarction
and development of epilepsy, were seen in 24 % of the
cases, which is comparable to other reports [16, 31, 32].
Other neurological complications were documented,
such as brain oedema and neurocognitive problems. A
recent publication showed impaired neuromotor outcome
in all patients included [33]. Unfortunately, we have
no comparable documentation on the long term neu-
romotor function in this study.
Interestingly, 61 % in the D+HUS group were
treated with antibiotics prior to and/or during initial
hospitalization, although for several indications. This
included sepsis, which was documented in 29 %.
There has been disagreement on the use of antibiotics
in both STEC and STEC-HUS cases. The current
consensus advices against the use of antibiotics in
STEC infections because of an assumed increased risk
for HUS development as a consequence of toxin release
[34]. Studies have shown variable results, and the use of
antibiotics depends on several factors requiring a more
nuanced approach [35, 36]. The use of antibiotics in
established STEC-HUS is more controversial, although
studies have shown no influence on long-term outcome
[34]. We were not able to examine potential effects of
the use of antibiotics in our study as the time of admin-
istration was often unclear and the indication was
variable.
In the D+HUS cases where data on follow-up was
available 1 year or more following initial admission,
21 % had persistent hypertension, 32 % persistent pro-
teinuria and 8 % developed chronic kidney disease,
one with need of a kidney transplant. These numbers
are comparable to those described in other studies
[20, 37]. The results are likely overestimated as a con-
sequence of selective patient follow-up according to
disease severity. Interestingly, previous studies have
shown that some patients can develop sequelae such
as hypertension and proteinuria several years after
initial admission, even when showing no signs of
sequelae in early follow-up [37]. This had led to the
recommendations of follow up controls for at least
5 years for D+HUS patients. The case fatality rate in
Table 3 Laboratory data in HUS in children in Norway, 1999–2008
Laboratory feature Diarrhoea-associated HUS (N = 38) Non-diarrhea-associated HUS (N = 9)
Hemoglobin at admission (median, g/dL) 11.1 (7.8–12.7) (N = 31) 6.7 (6.2–7.2) (N = 7)
Hemoglobin, minimum value (median, g/dL) 6.5 (5.8–7,5) 6.0 (5.9–6.2) (N = 8)
Creatinine at admission <1y (median, μmol/L) 35 (31–250) (N = 3) 86 (61–110) (N = 2)
Creatinine at admission ≥1y (median, μmol/L) 135 (61–275) (N = 25) 115 (110–132) (N = 5)
Creatinine, maximum value <1y (median, μmol/L) 231 (197–348) (N = 3) 97 (67–126) (N = 2)
Creatinine, maximum value ≥1y (median, μmol/L) 355 (200–465) (N = 35) 228 (124–307) (N = 6)
eGFR at admission <1y (median, ml/min/1,73 m2) 42.8 (23.0–49.1) (N = 3) 21.8 (12.4–31.2) (N = 2)
eGFR at admission ≥1y (median, ml/min/1,73 m2) 16.4 (11.0–58.5) (N = 25) 19.4 (18.5–28.0) (N = 5)
eGFR, minimum value <1y (median, ml/min/1,73 m2) 6.5 (4.9–7.8) (N = 3) 21.6 (12.1–31.0) (N = 2)
eGFR, minimum value ≥1y (median, ml/min/1,73 m2) 15.0 (6.3–13.8) (N = 35) 13.9 (7.6–21.8)
LDa at admission (median, U/L) 2241 (1153–2728) (N = 17) 2075 (1863–2659) (N = 5)
LD, maximum value (median, U/L) 3146 (2559–4023) 3090 (2441–5931) (N = 7)
Platelet count at admission (median, ×109/L) 59 (39–175) (N = 30) 39 (24–107) (N = 7)
Platelet count, minimum value (median, ×109/L) 32 (20–50) 24 (19–55) (N = 8)
CRPb at admission (median, mg/L) 14 (9–30) (N = 30) 13 (2–21) (N = 6)
CRP, maximum value (median, mg/L) 67 (19–138) (N = 37) 29 (15–161) (N = 7)
WBCc count at admission (median, ×109/L) 17.0 (11.2–25.4) (N = 29) 11.6 (9.4–14.1) (N = 7)
WBC count, maximum value (median, ×109/L) 19.4 (15.1–29.4) 16.0 (14.4–17.4) (N = 8)
Sodium at admission (median, μmol/L) 134 (130–137) (N = 27) 135 (130–135) (N = 6)
Results are presented as number of cases, n (%) and median (interquartile range). If data on the feature was not available in all medical records, the number of
cases where available is presented with (N = number of cases where available). Estimated glomerular filtration rate (eGFR) was estimated retrospectively using the
height-independent Pottel eGFR equation [29]. HUS hemolytic uremic syndrome
aLD Lactate dehydrogenase
bCRP C-reactive protein
cWBC white blood cell
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the D+HUS group was 5 %. This rate varies between
studies, and is often higher during outbreaks, but is
usually considered 3–5 % [4, 21].
In the D−HUS group, five of the nine patients were
oligoanuric and of these three needed dialysis. In the
study from Constantinescu [11] the renal complica-
tions of the D−HUS group were seemingly more
pronounced than we could document. However, the
number of cases in our study was low, which could
have influenced the results. It should also be noted
that the cases included here were treated before
Eculizumab was introduced as an effective treatment
in genetic HUS [25].
Only two patients were diagnosed with SP-HUS. Both
were severely sick in the acute phase as a complication
of their pneumococcal infection. SP-HUS is generally
considered more lethal in the acute phase and D−HUS
associated with more frequent long-term complications
than D+HUS [11, 22]. In our study, the long-term
consequences documented in SP-HUS were sustained
bilateral loss of hearing, epileptic activity and spastic
hemiplegia, but none of the two patients died.
There were limitations in this study. Firstly, due to
the small size of the groups and different etiologies of
the D−HUS group, comparison between them and to
other studies was difficult and only descriptive results
are therefore presented. Secondly, there was one out-
break of STEC leading to HUS in the 10-year period
described here. This occurred in 2006 and included
nine patients with STEC-HUS caused by STEC
O103:H25 [27]. This outbreak seemingly had an un-
usually high STEC-HUS to STEC ratio, potentially
caused by a particularly virulent strain. The outbreak
constitute one fourth of the D+HUS group in this
study, and may have affected the results presented.
Another issue that has to be addressed is the inclusion
criteria and the considerations around inclusion of
some of the cases that did not strictly fulfill the
criteria. Serum creatinine was chosen instead of the
pRIFLE criteria because a pilot project revealed diffi-
culties in retrospectively obtaining data on urinary
output in the medical records. We did not predict
the problem with such a steep rise from one to 2 years
of age in these criteria. If followed categorically, this
would have excluded five cases. Three D+HUS cases
and one D−HUS case had clinical HUS and serum
creatinine below 80 μmol/L, but above laboratory age-
related reference level at the hospitals in question. We
decided to include them as regular HUS cases. A
second D−HUS case had two admissions with reduced
kidney function and falling serum hemoglobin and
platelets, albeit not below our criteria. This case had an
extensive family history of genetic HUS, confirmed cor-
responding mutations and later had recurring milder
episodes. This would be considered a partial HUS case,
but we decided to include it, albeit not in all estima-
tions of clinical aspects. A sixth patient died early in
the acute phase, with s-hemoglobin value only docu-
mented at admission and higher than required in our
criteria. This patient had confirmed STEC infection.
These cases were included after consulting a clinician
with expertise in pediatric nephrology.
These challenges highlight some important limita-
tions to these types of studies, especially when evalu-
ating an extensive amount of data. There are two
important factors in particular that need to be com-
mented. One; we designed the data collection form
from a pilot study of HUS medical records to assess
which parameters where both relevant and available.
Two; data collected from medical records were subject
to the standards of different hospitals, clinicians and
the subjective (and objective) opinions of the latter.
Certain parameters were generally fixed and difficult to
misinterpret, others were not. For example; “duration
of initial hospitalization” was not subject to misinter-
pretation as the dates followed the medical records. On
the other hand, “time from first symptom to admit-
tance” was subject to uncertainty according to how
clinicians had perceived disease progression (e.g. “a
couple of days” or similar).
Another limitation is the consistency in a retrospective
survey of medical records to provide all necessary data.
All medical records and associated charts were exam-
ined thoroughly. However, we were only able to obtain
measures of blood pressure at admittance in 23 cases.
This only allowed us to assess blood pressure at admit-
tance in less than half the cases, illustrating the potential
for missing data in retrospective surveys.
Conclusions
We have presented the clinical features, therapeutic in-
terventions and long-term aspects of hemolytic-uremic
syndrome in children in Norway over a 10-year period.
A nationwide collection of data has allowed us to
include all cases that occurred within this time span,
describing this life-threatening condition on which
knowledge concerning disease burden and outcome was
limited. The data reports on the multi-organ affection in
this disease entity with a high numbers of serious com-
plications. These include a considerable number of cases
with severe complications from the central nervous
system, with brain micro infarctions and edema and
development of epilepsy, of cardiac nature, such as
myocardial infarction, in the gastrointestinal tract, such
as colonic perforation and subsequent peritonitis, the
respiratory system, such as acute respiratory failure, and
a large proportion developing sepsis in the acute phase.
These data underline that HUS patients have to be
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monitored carefully for extra-renal involvement in the
acute phase. There were also a considerable number of
cases showing long-term kidney related sequelae. Chil-
dren with symptoms suspicious of HUS should be
treated at centers with experience and possibilities for
thorough monitoring. Through this and previous studies,
we would like to emphasize the importance of thorough
long-term follow-up and the need for quality guidelines
to ensure this aspect of patient care in patients affected
by HUS.
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